Fig. 3: Survival in the MEAP and SIEAP. | British Journal of Cancer

Fig. 3: Survival in the MEAP and SIEAP.

From: Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial

Fig. 3: Survival in the MEAP and SIEAP.

Kaplan–Meier curves of progression-free survival (a) and overall survival (b). Tumour response was assessed by IRRC per RECIST v1.1. CI confidence interval, IRRC independent radiological review committee, MEAP main efficacy analysis population, mo month, NR not reached, OS overall survival, PFS progression-free survival, RECIST Response Evaluation Criteria in Solid Tumors, SIEAP special-interest efficacy analysis population.

Back to article page